[PDF][PDF] Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced …

J Cortés, P Fumoleau, GV Bianchi, TM Petrella… - J Clin Oncol, 2012 - academia.edu
J Cortés, P Fumoleau, GV Bianchi, TM Petrella, K Gelmon, X Pivot, S Verma, J Albanell…
J Clin Oncol, 2012academia.edu
Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate
(CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)–positive
breast cancer whose disease progressed during prior trastuzumab-based therapy. To define
whether this previously observed encouraging activity was a result of the combination of
pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients
who received pertuzumab without trastuzumab. We then investigated the impact of …
Purpose
The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy.
academia.edu